Gilead's Trodelvy meets Phase 3 endpoint in HR+/HER2- metastatic breast cancer

GILEAD SCIENCES, INC.

TROPiCS-02 met primary endpoint: statistically significant PFS improvement vs physician's choice chemo in 543 patients.
First interim OS analysis showed numerical improvement but not statistically significant; final OS readout expected in 2024.
Safety profile consistent with prior studies; no new safety concerns observed.
Gilead reaffirms 2022 guidance; oncology revenue goal of 1/3 by 2030 unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.